CD4<200且HIV-RNA>5 log10患者初始ART方案的持久性比较
该回顾性队列研究纳入ICONA队列中CD4+<200 cells/mm3且HIV-RNA>5 log10 copies/mL的1195例初治HIV感染者,比较bPI、NNRTI和InSTI三类锚定药物方案的持久性。随访2759人年,642例发生治疗失败;以NNRTI为参照,bPI方案失败风险更高(aIRR 1.62,95%CI 1.29-2.03,P<0.001),InSTI方案失败风险更低(aIRR 0.68,95%CI 0.48-0.96,P=0.03)。结论提示InSTI方案的持久性优于NNRTI和bPI方案。
要点
- CD4<200且HIV-RNA>5 log10者,InSTI方案持久性优于NNRTI和bPI方案
- bPI方案治疗失败风险显著高于NNRTI(aIRR 1.62,P<0.001)
- InSTI方案治疗失败风险低于NNRTI(aIRR 0.68,P=0.03)
核心结论
- 在CD4+<200 cells/mm3且HIV-RNA>5 log10 copies/mL的初治患者中,InSTI为基础方案的持久性长于NNRTI和bPI为基础方案。
研究设计与样本
- 回顾性研究,纳入ICONA队列中前瞻性随访的HIV感染者,共1195例,其中bPI组696例、InSTI组315例、NNRTI组184例,随访2759人年。
主要发现
- 随访期间642例发生治疗失败(TF,定义为治疗6个月后连续两次HIV-RNA>50 copies/mL的首次、锚定药物类别停药或死亡)。
- 以NNRTI为参照,bPI方案与TF独立相关(aIRR 1.62,95%CI 1.29-2.03,P<0.001)。
- 以NNRTI为参照,InSTI方案与TF独立相关(aIRR 0.68,95%CI 0.48-0.96,P=0.03)。
临床怎么用
- 对CD4+<200 cells/mm3且HIV-RNA>5 log10 copies/mL的初治患者,可优先考虑InSTI为基础方案以提高持久性。
局限性
- 为回顾性队列研究,非随机分组,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our aim was to investigate the durability of different initial regimens in patients starting ART with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. METHODS: This was a retrospective study of HIV-infected patients prospectively followed in the ICONA cohort. Those who started ART with boosted protease inhibitors (bPIs), NNRTIs or integrase strand transfer inhibitors (InSTIs), with CD4+ <200 cells/mm3 and HIV-RNA >5 log10 copies/mL, were included. The primary endpoint was treatment failure (TF), a composite endpoint defined as virological failure (VF, first of two consecutive HIV-RNA >50 copies/mL after 6 months of treatment), discontinuation of class of the anchor drug or death. Independent associations were investigated by Poisson regression analysis in a model including age, gender, mode of HIV transmission, CDC stage, HCV and HBV co-infection, pre-treatment HIV-RNA, CD4+ count and CD4+/CD8+ ratio, ongoing opportunistic disease, fibrosis FIB-4 index, estimated glomerular filtration rate, haemoglobin, platelets, neutrophils, calendar year of ART initiation, anchor drug class (treatment group) and nucleos(t)ide backbone. RESULTS: A total of 1195 patients fulfilled the inclusion criteria: 696 started ART with a bPI, 315 with an InSTI and 184 with an NNRTI. During 2759 person-years of follow up, 642 patients experienced TF. Starting ART with bPIs [adjusted incidence rate ratio (aIRR) (95% CI) 1.62 (1.29-2.03) versus starting with NNRTIs; P < 0.001] and starting ART with InSTIs [aIRR (95% CI) 0.68 (0.48-0.96) versus starting with NNRTIs; P = 0.03] were independently associated with TF. CONCLUSIONS: In patients starting ART with <200 CD4+ cells/mm3 and >5 log10 HIV-RNA copies/mL, the durability of regimens based on InSTIs was longer than that of NNRTI- and bPI-based regimens.
引用
- Gianotti N, Lorenzini P, Cozzi-Lepri A, et al. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. J Antimicrob Chemother. 2019. PMID: 31173639. doi:10.1093/jac/dkz237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。